Increase in FeNO Levels Following IL5/IL5R-Targeting Therapies in Severe Asthma: A Case Series

Increase in FeNO Levels Following IL5/IL5R-Targeting Therapies in Severe Asthma: A Case Series

Geneviève Pelletier,1 Krystelle Godbout,1,2 Marie-Ève Boulay,1 Louis-Philippe Boulet,1,2 Mathieu C Morissette,1,2 Andréanne Côté1,2 1Quebec Heart and Lung Institute – Laval University, Quebec, QC, Canada; 2Department of Medicine, Faculty of Medicine, Laval University, Quebec, QC, CanadaCorrespondenc...

Full description

Bibliographic Details
Main Authors:	Pelletier G, Godbout K, Boulay MÈ, Boulet LP, Morissette MC, Côté A
Format:	Article
Language:	English
Published:	Dove Medical Press 2022-05-01
Series:	Journal of Asthma and Allergy
Subjects:	biologics biomarkers benralizumab mepolizumab
Online Access:	https://www.dovepress.com/increase-in-feno-levels-following-il5il5r-targeting-therapies-in-sever-peer-reviewed-fulltext-article-JAA

Similar Items

Impact of Anti-IL5 Therapies on Patients with Severe Uncontrolled Asthma and Possible Predictive Biomarkers of Response: A Real-Life Study
by: Susana Rojo-Tolosa, et al.
Published: (2023-01-01)

Combining Biologics Targeting Eosinophils (IL-5/IL-5R), IgE, and IL-4/IL-13 in Allergic and Inflammatory Diseases
by: Mitchell M. Pitlick, MD, et al.
Published: (2022-11-01)

The effect of anti-IL5 monoclonal antibodies on regulatory and effector T cells in severe eosinophilic asthma
by: Laura Bergantini, et al.
Published: (2023-10-01)

Safety and efficacy of monoclonal antibodies targeting IL-5 in severe eosinophilic asthma: A systematic review and meta-analysis of randomized controlled trials
by: Noor Alam, et al.
Published: (2023-09-01)

Severe Asthma Remissions Induced by Biologics Targeting IL5/IL5r: Results from a Multicenter Real-Life Study
by: Angelantonio Maglio, et al.
Published: (2023-01-01)

Treatment Challenges in Severe Eosinophilic Asthma: Differential Response to Anti-IL-5 and Anti-IL-5R Therapy
by: Agamemnon Bakakos, et al.
Published: (2021-04-01)

Characterization of Severe Uncontrolled Asthma in Japan: Analysis of Baseline Data from the PROSPECT Study
by: Koya T, et al.
Published: (2023-06-01)

Exploring the risk of infection events in patients with asthma receiving anti-IL-5 monoclonal antibodies: A rapid systematic review and a meta-analysis
by: Riccardo Giossi, et al.
Published: (2024-01-01)

Benralizumab in Patients with Severe Eosinophilic Asthma: A Multicentre Real-Life Experience
by: Giulia Scioscia, et al.
Published: (2023-06-01)

Efficacy of tezepelumab against uncontrolled severe non‐type 2 asthma refractory to bronchial thermoplasty, benralizumab, dupilumab and mepolizumab
by: Yoshiro Kai, et al.
Published: (2024-03-01)

Nasal Symptoms in Asthmatic Patients under Treatment with Anti-IL-5 Monoclonal Antibodies. A Real-Life Cohort Study
by: Juan Maza-Solano, et al.
Published: (2022-11-01)

Successful simultaneous targeting of IgE and IL-5 in a severe asthmatic patient selected for lung transplantation
by: Karl-Christian Bergmann, PhD, MD, et al.
Published: (2022-08-01)

Taking a Breather: Advances in Interleukin 5 Inhibition for Asthma Relief
by: Oliver William Massey, et al.
Published: (2022-09-01)

Elaborate biologic approval process delays care of patients with moderate-to-severe asthma
by: Esha Sehanobish, PhD, et al.
Published: (2023-05-01)

Evidence-Based Approach of Biologic Therapy in Bronchial Asthma
by: Adnan Liaqat, et al.
Published: (2023-06-01)

Adverse events of anti-IL-5 drugs in patients with eosinophilic asthma: a meta-analysis of randomized controlled trials and real-world evidence-based assessments
by: Wen Li, et al.
Published: (2024-02-01)

IL13 May Play an Important Role in Developing Eosinophilic Chronic Rhinosinusitis and Eosinophilic Otitis Media with Severe Asthma
by: Hideyasu Shimizu, et al.
Published: (2021-10-01)

Initiation, response assessment, and switch of antibody therapies in patients with severe asthma – A survey among German specialists
by: Hendrik Suhling, MD, et al.
Published: (2023-12-01)

Effectiveness and safety of anti-IL-5/Rα biologics in eosinophilic granulomatosis with polyangiitis: a two-year multicenter observational study
by: Santi Nolasco, et al.
Published: (2023-06-01)

Effects of Therapeutic Antibodies on Gene and Protein Signatures in Asthma Patients: A Comparative Systematic Review
by: Maria J. Martin, et al.
Published: (2022-01-01)

Clinical characteristics of complete responders versus non-complete responders to omalizumab, benralizumab and mepolizumab in patients with severe asthma: a long-term retrospective analysis
by: Maria Basagaña, et al.
Published: (2024-12-01)

Management of Severe Asthma in Eosinophilic Granulomatosis with Polyangiitis with Interleukin-5-Targeted Therapies: Current Status and Report of Two Cases
by: Ciro Romano, et al.
Published: (2022-11-01)

Unanswered questions on the use of biologics in pediatric asthma
by: Antonio Nieto, MD, PhD, et al.
Published: (2023-11-01)

Mabs for treating asthma: omalizumab, mepolizumab, reslizumab, benralizumab, dupilumab
by: Erminia Ridolo, et al.
Published: (2020-10-01)

Monoclonal antibodies targeting small airways: a new perspective for biological therapies in severe asthma
by: Carlo Lombardi, et al.
Published: (2022-10-01)

Biological Therapy of Severe Asthma and Nasal Polyps
by: Agamemnon Bakakos, et al.
Published: (2022-06-01)

Changes in Serum MicroRNAs after Anti-IL-5 Biological Treatment of Severe Asthma
by: Manuel J. Rial, et al.
Published: (2021-03-01)

Long-term multicenter comparison shows equivalent efficacy of monoclonal antibodies in severe asthma therapy
by: Moritz Z. Kayser, et al.
Published: (2024-03-01)

Benralizumab Efficacy in Late Non-Responders to Mepolizumab and Variables Associated with Occurrence of Switching: A Real-Word Perspective
by: Marco Caminati, et al.
Published: (2023-02-01)

A systematic review and integrated analysis of biologics that target Type 2 inflammation to treat COPD with increased peripheral blood eosinophils
by: Hiroshi Ohnishi, et al.
Published: (2022-06-01)

The New Therapeutic Frontiers in the Treatment of Eosinophilic Esophagitis: Biological Drugs
by: Erminia Ridolo, et al.
Published: (2024-01-01)

Serum Proteomic Profile of Asthmatic Patients after Six Months of Benralizumab and Mepolizumab Treatment
by: Lorenza Vantaggiato, et al.
Published: (2022-03-01)

Role of Cytokines in EGPA and the Possibility of Treatment with an Anti-IL-5 Antibody
by: Takeo Isozaki, et al.
Published: (2020-11-01)

Anti-IL-5 therapy in patients with severe eosinophilic asthma – clinical efficacy and possible criteria for treatment response
by: Nora Drick, et al.
Published: (2018-07-01)

Severe Asthma or Chronic Obstructive Pulmonary Disease with Eosinophilic Inflammation? From Uncertainty to Remission under Anti IL-5R Therapy
by: Bianca Oprescu, et al.
Published: (2024-02-01)

Severe Asthma and Biological Therapies: Now and the Future
by: Olaia Sardon-Prado, et al.
Published: (2023-09-01)

Pretreatment Frequency of Circulating Th17 Cells and FeNO Levels Predicted the Real-World Response after 1 Year of Benralizumab Treatment in Patients with Severe Asthma
by: Yuuki Sandhu, et al.
Published: (2023-03-01)

New therapy options for patients with eosinophilic type of severe bronchial asthma
by: G. L. Ignatova, et al.
Published: (2020-01-01)

Anti-IL5/IL5R Treatment in COPD: Should We Target Oral Corticosteroid-Dependent Patients?
by: Laroche J, et al.
Published: (2023-05-01)

Low-dose anti-IL 5 treatment in idiopathic hypereosinophilic syndrome: towards a precision medicine approach for remission maintenance
by: Marco Caminati, et al.
Published: (2023-09-01)